Wolverine Trading
HRTX icon

Wolverine Trading’s Heron Therapeutics HRTX Stock Holding History

Wolverine Trading’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-17,900
Closed -$62.6K – 5037
2024
Q2 		$62.6K Buy
17,900
+6,600
+58% +$20.3K ﹤0.01% 4182
2024
Q1 		$31.3K Buy
11,300
+100
+0.9% +$251 ﹤0.01% 4292
2023
Q4 		$19K Buy
+11,200
New +$12.3K ﹤0.01% 4373
2022
Q3 		– Sell
-12,100
Closed -$38K – 4903
2022
Q2 		$38K Sell
12,100
-47,500
-80% -$191K ﹤0.01% 4130
2022
Q1 		$339K Buy
+59,600
New +$436K ﹤0.01% 3741
2021
Q3 		– Sell
-16,700
Closed -$261K – 6536
2021
Q2 		$261K Sell
16,700
-2,400
-13% -$38.2K ﹤0.01% 4632
2021
Q1 		$292K Buy
19,100
+5,300
+38% +$94.5K ﹤0.01% 4505
2020
Q4 		$294K Buy
+13,800
New +$240K ﹤0.01% 3765
2020
Q3 		– Sell
-29,600
Closed -$422K – 4789
2020
Q2 		$422K Sell
29,600
-20,000
-40% -$329K ﹤0.01% 2927
2020
Q1 		$580K Buy
49,600
+3,800
+8% +$71.4K ﹤0.01% 2481
2019
Q4 		$1.08M Buy
45,800
+18,600
+68% +$412K ﹤0.01% 2342
2019
Q3 		$533K Sell
27,200
-63,600
-70% -$1.17M ﹤0.01% 2568
2019
Q2 		$1.69M Buy
90,800
+71,600
+373% +$1.43M ﹤0.01% 1632
2019
Q1 		$469K Sell
19,200
-31,000
-62% -$812K ﹤0.01% 2851
2018
Q4 		$1.19M Buy
50,200
+3,400
+7% +$93.5K ﹤0.01% 1825
2018
Q3 		$1.48M Sell
46,800
-20,500
-30% -$764K ﹤0.01% 1947
2018
Q2 		$1.86M Hold
67,300
– – ﹤0.01% 1660
2018
Q1 		$1.86M Buy
67,300
+31,300
+87% +$710K ﹤0.01% 1660
2017
Q4 		$652K Buy
36,000
+2,300
+7% +$37.5K ﹤0.01% 2685
2017
Q3 		$544K Buy
33,700
+14,400
+75% +$226K ﹤0.01% 2521
2017
Q2 		$268K Sell
19,300
-7,300
-27% -$106K ﹤0.01% 3202
2017
Q1 		$406K Buy
+26,600
New +$368K ﹤0.01% 2649
2016
Q4 		– Sell
-14,700
Closed -$251K – 4717
2016
Q3 		$251K Buy
+14,700
New +$273K ﹤0.01% 3488

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wolverine Trading's HRTX Position: Q1 2025 in Review

Wolverine Trading sold out of Heron Therapeutics (HRTX) in Q1 2025, closing a stake of 12,330 shares — an estimated $18.6K sold.

Wolverine Trading first reported a position in HRTX in Q1 2018 and held it in 14 quarters. The position peaked at $1.22M in Q2 2018. 164 funds tracked by Wall St. Rank hold HRTX as of Q1 2025.

  • Wolverine Trading reported no remaining Heron Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Wolverine Trading sold 12,330 Heron Therapeutics shares in Q1 2025, an estimated $18.6K.
  • Wolverine Trading first reported a position in Heron Therapeutics in Q1 2018 and held it in 14 quarters.
  • Wolverine Trading's Heron Therapeutics position peaked at $1.22M in Q2 2018.
  • 164 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2025.

Based on Wolverine Trading's 13F filing for Q1 2025, filed 15 May 2025.